The Germline PGx Services Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract, awarded by the Department of Veterans Affairs (VA) Strategic Acquisition Center-Frederick on September 30, 2024, provides national access to germline genetic testing and pharmacogenomic molecular testing services for the VA enterprise. The contract encompasses three primary service lines: oncology genetic testing, medical genetics testing, and pharmacogenomics testing, all designed to support personalized medicine and optimize pharmaceutical treatment for veteran populations. Contractors under this vehicle must provide all necessary personnel, equipment, supplies, facilities, and services to perform testing in compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations, the Clinical Laboratory Improvement Act, and other applicable standards. The vehicle operates under a shared ceiling of approximately $99.0 million with a final ordering date of September 29, 2029, enabling the VA to flexibly issue task orders across its Oncology, Medical Genetics, and Pharmacogenomics practice sites as demand for services evolves.
The awarded task orders demonstrate that the VA has selected multiple prime contractors to deliver these services, with Fulgent Therapeutics LLC and Baylor Miraca Genetics Laboratories LLC (doing business as Baylor Genetics) as primary awardees. Individual delivery orders range from approximately $982,000 to $11.4 million, with durations typically spanning one to five years through the September 2029 master contract expiration. The task orders issued to date total approximately $21.9 million in obligated funds, representing year-one and year-two service offerings with firm fixed-price structures that provide cost predictability. All delivery orders have been issued without set-aside designations, indicating unrestricted competition among the multiple prime contractors. Performance locations are primarily in Frederick, Maryland, where the Strategic Acquisition Center is located, and the contracting vehicle supports the VA's National Oncology Program, National Genomic Medicine Program, and National Pharmacogenomics Program initiatives.